ZEVRA THERAPEUTICS, INC.
CELEBRATION, FLORIDA

When prodrugs are administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm’s ability to discover the unique parent drug-ligand chemical combination differentiates our prodrugs from other drug products on the market. Fundamentally we create new molecules that can impart key advantages, enabling the creation of potentially safer, more effective and therefore differentiated products. has employed its LAT™ prodrug platform to create a portfolio of product candidates that we believe will offer significant improvements over FDA-approved and widely prescribed drugs. has been and continues to be a prodrug discovery company focused on building a portfolio of prodrugs that represent an improvement over currently approved drugs and address unmet medical needs in large, established markets. Prodrugs offer an attractive risk-reward profile in that prodrugs can both improve the performance of the parent drug and offer a developmental time horizon that is vastly shorter than a traditional new chemical entity. Moreover, because prodrugs are considered new molecular entities they may be eligible for patent protection as novel compositions of matter, provided that all other applicable requirements are met. Composition-of-matter patent protection. KemPharm’s prodrugs are new molecules and thus may be eligible for patent protection as novel compositions of matter, provided that all other applicable requirements are met. Our strategy is to seek patent protection not only for our prodrug product candidates, but also for related compounds with the intention of creating heightened barriers to market entry. KemPharm’s LAT™ platform technology allows the company to develop prodrugs that may be eligible to use the 505(b)(2) NDA pathway. Under that regulatory pathway, if KemPharm is able to demonstrate the bioequivalence of one of its product candidates to an appropriate approved drug, we will then be able to reference the FDA’s previous findings of safety and effectiveness for the approved drug in our 505(b)(2) NDA submissions. This may allow us to avoid the significant time and expense of conducting large clinical trials and eliminate the need for some preclinical activities. Our products have improved properties over approved drugs and address unmet medical needs in large, established markets. Products & Possibilities We worked with JLB to completely rebrand our business from logo to print ads to website. We are so pleased with the way everything turned out — the JLB team has a great sense of style and is flexible and clever. We get compliments on our website on a daily basis, and clients tell us it’s the best interior design site they’ve seen. There is no doubt that JLB’s work has driven a lot of new business our way. It’s remarkable working with a team that treats your business as they would their own with drive, innovation, humility, and a shared love of bringing great things to the wonderful Franklin community. As a firm, we were ready to re-invent our web presence and brand. JLB came highly recommended. They completely rebuilt our logo and website as well has helped craft our marketing efforts. We are very pleased with JLB. There were a number of website design companies that would have done an adequate job for our company. The difference was that JLB wanted to be our partner. JLB listened to our needs, then served our concerns and desires through the entire process. Even after the completion of the project they have continued to support, guide, and enhance our company with cutting edge technology. STAR has been blessed to have them as a teammate Choosing JLB has been a great decision! We are fortunate to have JLB be a part of the BMC Metalwork's future as we continue to enhance our business